Journal Title
Title of Journal: Curr Hypertens Rep
|
Abbravation: Current Hypertension Reports
|
|
|
|
|
Authors: Rebecca C Moorhouse David J Webb David C Kluth Neeraj Dhaun
Publish Date: 2013/08/04
Volume: 15, Issue: 5, Pages: 489-496
Abstract
Hypertension contributes greatly to global disease burden and in many patients current treatments do not adequately control blood pressure BP Endothelin1 ET1 is a potent vasoconstrictor that is implicated in the pathogenesis of hypertension including the hypertension that is often associated with chronic kidney disease CKD and the metabolic syndrome ET receptor antagonists currently licensed for the treatment of pulmonary arterial hypertension and sclerodermarelated digital ulcers are being investigated for the treatment of hypertension Clinical trials have addressed the use of ET receptor antagonists as monotherapy in primary hypertension as an addon therapy in resistant hypertension and in CKD This review will evaluate the current evidence regarding the therapeutic potential of ET receptor antagonists in hypertension as well as highlighting important issues that still need to be addressedRebecca C Moorhouse declares that she has no conflict of interest David J Webb has served as a consultant to and received grants from Pfizer David C Kluth declares that he has no conflict of interest Neeraj Dhaun has received grants from Pfizer
Keywords:
.
|
Other Papers In This Journal:
|